The blood-brain barrier (BBB) prevents neurotoxic plasma components, blood cells, and
pathogens from entering the brain. At the same time, the BBB regulates transport of …

Alzheimer's disease, the leading cause of dementia in the elderly, is a neurodegenerative
condition characterized by accumulation of amyloid plaques and neurofibrillary tangles in …

Alzheimer's disease (AD) is pathologically defined by the presence of fibrillar amyloid β (Aβ)
peptide in extracellular senile plaques and tau filaments in intracellular neurofibrillary …

The blood–brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and
pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in …

The blood coagulation protein fibrinogen is deposited in the brain in a wide range of
neurological diseases and traumatic injuries with blood–brain barrier (BBB) disruption …

The amyloid-beta peptide (Aβ) is a driver of Alzheimer's disease (AD). Aβ monomers can
aggregate and form larger soluble (oligomers/protofibrils) and insoluble (fibrils) forms. There …

Background: Cerebrovascular disease is a common comorbidity in patients with Alzheimer's
disease (AD). It is believed to contribute additively to the cognitive impairment and to lower …

Inhibiting thrombosis without generating bleeding risks is a major challenge in medicine. A
promising solution may be the inhibition of coagulation factor XII (FXII), because its knock …

The societal burden of Alzheimer's disease (AD) is staggering, with current estimates
suggesting that 50 million people world-wide have AD. Identification of new therapeutic …

The blood platelet plays an important role but often remains under‐recognized in several
vascular complications and associated diseases. Surprisingly, platelet hyperactivity and …